SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Jacqueline du Pré

PatientJacqueline Mary du Pré
Date of birth1998-01-26
IdentifiersMRN HR-ML039-SYN; SSN (made up) 000-39-7062
Document date2026-10-12
AuthorImogen Thackeray-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six months: first 600 mg dose of ocrelizumab. [S]

History of Present Illness

Ms. du Pré comes on the day of her first 600 mg dose of ocrelizumab, six months after starting treatment. She has had no relapse and no new symptoms. She played chamber music in public in August and last month, has a concerto booked for the spring, and gives master classes at a conservatory twice a month. Faint tingling in the left fingertips comes only after long practice. Fatigue is manageable with swimming and an after-lunch rest. She had influenza and COVID-19 vaccines a month ago. She asked when it would be safe to try for a baby, perhaps in a year or two. [S]

ElementDetail
Disease activityNo relapse in six months; re-baseline MRI clear
TreatmentOcrelizumab 600 mg today
MusicPerforming chamber music; concerto booked; teaching master classes
Her questionPregnancy in a year or two

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy manageable; no fever
NeurologicalPositiveFaint tingling in the left fingertips after long practice only
GenitourinaryNegativeNo urinary symptoms
RespiratoryNegativeNo cough
MusculoskeletalNegativeNeck stiffness after practice, better with stretching
PsychiatricNegativeHappy to be playing; PHQ-9 3, GAD-7 3; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 daysOne capsule twice daily for 5 daysOral route2026-06-15 to 2026-06-19completedS
Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days1 g daily for 3 daysIntravenous route2026-03-24 to 2026-03-26completedS
Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth dailyOne capsule dailyOral route2026-03-23activeS
Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion300 mg on days 1 and 15, then 600 mg every 6 monthsIntravenous route2026-04-13activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-12Body height173cmS
2026-10-12Body weight63.8kgS
2026-10-12Body mass index (BMI) [Ratio]21.3kg/m2S
2026-10-12Systolic blood pressure112mm[Hg]S
2026-10-12Diastolic blood pressure70mm[Hg]S
2026-10-12Heart rate68/minS
2026-10-12Respiratory rate14/minS
2026-10-12Body temperature36.5CelS
2026-10-12Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-12Hemoglobin [Mass/volume] in Blood13.7g/dL12-15.5 g/dLNormalS
2026-10-12Leukocytes [#/volume] in Blood by Automated count610*3/uL4-11 10*3/uLNormalS
2026-10-12Lymphocytes [#/volume] in Blood by Automated count1.410*3/uL1-4.8 10*3/uLNormalS
2026-10-12Platelets [#/volume] in Blood by Automated count23810*3/uL150-400 10*3/uLNormalS
2026-10-12Creatinine [Mass/volume] in Serum or Plasma0.7mg/dL0.59-1.04 mg/dLNormalS
2026-10-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M121mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
2026-10-12Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L8-35 U/LNormalS
2026-10-12IgG [Mass/volume] in Serum or Plasma930mg/dL700-1600 mg/dLNormalS
2026-10-12IgM [Mass/volume] in Serum or Plasma46mg/dL40-230 mg/dLNormalS
2026-10-1225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma38ng/mLBelow 20 ng/mL deficient; 20 to 29 insufficientNormalS
2026-10-12Hepatitis B virus surface Ab [Units/volume] in Serum6m[IU]/mL10 mIU/mL or more is protectiveLowS
2026-10-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-10-12Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]3{score}S
2026-10-129-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox]18.5sS
2026-10-129-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox]19.5sS

Physical Exam

Vital signs recorded on 2026-10-12; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 63.8 kg; blood pressure 112/70
NeurologicalVibration slightly reduced in the left fingertips only; otherwise normal. Nine-hole peg test 18.5 seconds right, 19.5 seconds left. EDSS 1.0
SkinNo rash
PsychiatricBright and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this weekresolvedconfirmed R20.2S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit.
Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 2017 McDonald criteria and the 2024 revision; synthetic modern detail linked to her documented diagnosisactiveconfirmed G35.AS — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973.
Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosisactiveconfirmed E55.9S — Synthetic finding.
Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolvedresolvedconfirmed N30.00S — Synthetic intercurrent infection; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with lymphocytesBefore each ocrelizumab doseCompleted todayHemoglobin 13.7 g/dL, white cells 6.0, lymphocytes 1.4, platelets 238
LaboratoryImmunoglobulins (IgG, IgM)At baseline and before each ocrelizumab doseCompleted todayIgG 930 mg/dL, IgM 46 mg/dL (low-normal)
LaboratoryKidney and liver testsBefore each doseCompleted todayCreatinine 0.70 mg/dL, eGFR 121; ALT 18 U/L, AST 20 U/L
Laboratory25-hydroxyvitamin DEvery six to twelve months on replacementCompleted today38 ng/mL
LaboratoryHepatitis B surface antibody after vaccinationOne to two months after the last doseCompleted today6 mIU/mL, not protective; drawn late (deviation recorded at the fourth visit)
LaboratoryPregnancy testBefore each ocrelizumab doseCompleted todayUrine pregnancy test negative
ImagingMRI of the brainYearly on treatmentDueNext about a year after the re-baseline scan
ExaminationHand function: nine-hole peg test, both handsAt diagnosis, after a relapse, and at each reviewCompleted today18.5 seconds right, 19.5 seconds left
ExaminationNeurological examination and EDSSEach reviewCompleted todayEDSS 1.0; no change
Medication safetyInfections on anti-CD20 therapyEach reviewCompleted todayNone since June
SurveyMood and anxiety (PHQ-9, GAD-7)At diagnosis and at each reviewCompleted todayPHQ-9 3 (item 9 scored 0), GAD-7 3
Self-managementPregnancy planningAt each review in women who may become pregnantCompleted todayPlan to conceive a few months after a dose, with a preconception visit
Self-managementFatigue: causes and managementEach reviewCompleted todayManaged with exercise and pacing

Goal progress:

Guideline basis: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021); Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019)

Follow-up: Ocrelizumab every six months; MRI of the brain in about nine months; primary care review in six months; preconception visit when she is ready. [S]